Gavin Koh

3.1k total citations · 1 hit paper
43 papers, 1.5k citations indexed

About

Gavin Koh is a scholar working on Epidemiology, Infectious Diseases and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Gavin Koh has authored 43 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Epidemiology, 14 papers in Infectious Diseases and 11 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Gavin Koh's work include Burkholderia infections and melioidosis (12 papers), Malaria Research and Control (9 papers) and Tuberculosis Research and Epidemiology (7 papers). Gavin Koh is often cited by papers focused on Burkholderia infections and melioidosis (12 papers), Malaria Research and Control (9 papers) and Tuberculosis Research and Epidemiology (7 papers). Gavin Koh collaborates with scholars based in United Kingdom, Thailand and United States. Gavin Koh's co-authors include Sharon J. Peacock, W. Joost Wiersinga, Tom van der Poll, Richard J. Maude, Stuart D. Blacksell, Paul N. Newton, Daniel H. Paris, Nicholas Day, Direk Limmathurotsakul and Martin Dedicoat and has published in prestigious journals such as Nature Medicine, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Gavin Koh

42 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

2022 127 citations Hugh Montgomery, Richard Hobbs et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gavin Koh United Kingdom	21	544	497	297	275	193	43	1.5k
Laura Milazzo Italy	23	752 1.4×	679 1.4×	209 0.7×	244 0.9×	61 0.3×	75	2.0k
Chun‐Yu Lin Taiwan	24	417 0.8×	567 1.1×	318 1.1×	365 1.3×	45 0.2×	93	1.7k
Bert K. Lopansri United States	23	311 0.6×	428 0.9×	755 2.5×	225 0.8×	66 0.3×	57	1.7k
J. Carl Craft United States	25	755 1.4×	567 1.1×	282 0.9×	224 0.8×	193 1.0×	46	1.7k
Sylvie Abel Martinique	25	473 0.9×	1.1k 2.1×	364 1.2×	196 0.7×	85 0.4×	62	2.0k
Ursula Hollenstein Austria	26	399 0.7×	287 0.6×	214 0.7×	442 1.6×	280 1.5×	38	2.0k
Michael Osthoff Switzerland	21	430 0.8×	317 0.6×	122 0.4×	196 0.7×	52 0.3×	94	1.6k
Jorge Cervantes United States	24	408 0.8×	515 1.0×	184 0.6×	583 2.1×	160 0.8×	129	2.1k
Johannes Nemeth Switzerland	19	586 1.1×	782 1.6×	204 0.7×	229 0.8×	48 0.2×	61	1.5k
Síle F. Molloy United Kingdom	19	872 1.6×	782 1.6×	255 0.9×	110 0.4×	291 1.5×	36	1.7k

Countries citing papers authored by Gavin Koh

Since Specialization

Citations

This map shows the geographic impact of Gavin Koh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gavin Koh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gavin Koh more than expected).

Fields of papers citing papers by Gavin Koh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gavin Koh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gavin Koh. The network helps show where Gavin Koh may publish in the future.

Co-authorship network of co-authors of Gavin Koh

This figure shows the co-authorship network connecting the top 25 collaborators of Gavin Koh. A scholar is included among the top collaborators of Gavin Koh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gavin Koh. Gavin Koh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Diacon, Andreas H., Clifton E. Barry, Ray Y. Chen, et al.. (2024). A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature Medicine. 30(3). 896–904. 20 indexed citations

Hobbs, Richard, Hugh Montgomery, Francisco Padilla, et al.. (2023). Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial. Infectious Diseases and Therapy. 12(9). 2269–2287. 3 indexed citations

Tuffy, Kevin M., Anastasia A. Aksyuk, Tyler Brady, et al.. (2023). Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants. The Journal of Infectious Diseases. 228(8). 1055–1059. 2 indexed citations

Watson, James A, Robert J. Commons, Joel Tärning, et al.. (2022). The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis. eLife. 11. 15 indexed citations

Montgomery, Hugh, Richard Hobbs, Francisco Padilla, et al.. (2022). Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 10(10). 985–996. 127 indexed citations breakdown →

Addo, Juliet, et al.. (2022). Living with tuberculosis: a qualitative study of patients’ experiences with disease and treatment. BMC Public Health. 22(1). 1717–1717. 21 indexed citations

Goyal, Navin, Khadeeja Mohamed, Katie Rolfe, et al.. (2018). Application of the Stable Isotope Label Approach in Clinical Development—Supporting Dissolution Specifications for a Commercial Tablet Product with Tafenoquine, a Long Half-life Compound. The AAPS Journal. 20(4). 74–74. 12 indexed citations

Jean, Pamela L. St., Zhengyu Xue, Nick Carter, et al.. (2016). Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malaria Journal. 15(1). 97–97. 61 indexed citations

Beck, Hans‐Peter, Rahel Wampfler, Nick Carter, et al.. (2015). Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping. The Journal of Infectious Diseases. 213(5). 794–799. 23 indexed citations

10.

Jong, Hanna K de, Gavin Koh, Joris J. T. H. Roelofs, et al.. (2014). Limited role for ASC and NLRP3 during in vivo Salmonella Typhimurium infection. BMC Immunology. 15(1). 30–30. 25 indexed citations

11.

O’Shea, Matthew K., et al.. (2014). Time-to-Detection in Culture Predicts Risk of Mycobacterium tuberculosis Transmission: A Cohort Study. Clinical Infectious Diseases. 59(2). 177–185. 20 indexed citations

12.

Jong, Hanna K de, Gavin Koh, Ahmed Achouiti, et al.. (2014). Neutrophil extracellular traps in the host defense against sepsis induced by Burkholderia pseudomallei (melioidosis). Intensive Care Medicine Experimental. 2(1). 21–21. 31 indexed citations

13.

Jong, Hanna K de, Gavin Koh, Ingrid Bulder, et al.. (2014). Diabetes‐independent increase of factor VII‐activating protease activation in patients with Gram‐negative sepsis (melioidosis). Journal of Thrombosis and Haemostasis. 13(1). 41–46. 5 indexed citations

14.

Koh, Gavin, Ruben Bautista, Rapeephan R. Maude, et al.. (2013). Host Responses to Melioidosis and Tuberculosis Are Both Dominated by Interferon-Mediated Signaling. PLoS ONE. 8(1). e54961–e54961. 55 indexed citations

15.

Koh, Gavin, Katrin Breitbach, Kathrin Krause, et al.. (2013). Glyburide Reduces Bacterial Dissemination in a Mouse Model of Melioidosis. PLoS neglected tropical diseases. 7(10). e2500–e2500. 33 indexed citations

16.

Koh, Gavin, Alexander P. J. Vlaar, Jorrit J. Hofstra, et al.. (2012). In the critically ill patient, diabetes predicts mortality independent of statin therapy but is not associated with acute lung injury. Critical Care Medicine. 40(6). 1835–1843. 22 indexed citations

17.

Maude, Rapeephan R., Richard J. Maude, Maliwan Hongsuwan, et al.. (2012). Prospective observational study of the frequency and features of intra-abdominal abscesses in patients with melioidosis in northeast Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene. 106(10). 629–631. 17 indexed citations

18.

Peacock, Sharon J., Direk Limmathurotsakul, Yoel Lubell, et al.. (2012). Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes. PLoS neglected tropical diseases. 6(1). e1488–e1488. 74 indexed citations

19.

Hofstra, Jorrit J., Alexander P. J. Vlaar, Gavin Koh, et al.. (2012). Early intravenous unfractionated heparin and outcome in acute lung injury and acute respiratory distress syndrome – a retrospective propensity matched cohort study. BMC Pulmonary Medicine. 12(1). 43–43. 6 indexed citations

20.

Koh, Gavin, Pablo Porras, Bruno Aranda, Henning Hermjakob, & Sandra Orchard. (2012). Analyzing Protein–Protein Interaction Networks. Journal of Proteome Research. 11(4). 2014–2031. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact